SCHEMBL10191978

SCHEMBL10191978

CCNC(=O)NCCOc1ccc(C)cc1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.65
KMT2A Q03164 4/20 0.56
MEN1 O00255 3/20 0.56
POLB P06746 1/20 0.56
ALDH1A1 P00352 2/20 0.55
TP53 P04637 1/20 0.55
HPGD P15428 1/20 0.55
MAPK1 P28482 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
HSD17B10 Q99714 1/20 0.55
DRD2 P14416 1/20 0.53
DRD4 P21917 1/20 0.53
DRD3 P35462 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.52
MTNR1A P48039 1/20 0.51
MTNR1B P49286 1/20 0.51
LMNA P02545 1/20 0.51
GAA P10253 1/20 0.51
MAPT P10636 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21595955 0.83 NPC1 (0.73) NPC1KMT2AMEN1POLBALDH1A1
SCHEMBL171846 0.81 MTNR1A (0.75) NPC1KMT2AMEN1POLBALDH1A1
SCHEMBL11886540 0.81 NPC1 (0.65) NPC1KMT2AMEN1POLBALDH1A1
Hydrochloric Acid SCHEMBL30832634 0.80 MTNR1A (0.73) NPC1KMT2AMEN1POLBALDH1A1
SCHEMBL807668 0.80 NPC1 (0.69) NPC1KMT2AMEN1POLBALDH1A1
SCHEMBL1108079 0.79 KMT2A (0.67) NPC1KMT2AMEN1POLBALDH1A1
SCHEMBL10389706 0.79 NPC1 (0.67) NPC1KMT2AMEN1POLBALDH1A1
SCHEMBL10050488 0.77 RECQL (0.74) NPC1KMT2AMEN1POLBALDH1A1
SCHEMBL11309905 0.77 NPC1 (0.60) NPC1KMT2AMEN1POLBALDH1A1
SCHEMBL14410497 0.77 L3MBTL1 (0.73) NPC1KMT2AMEN1POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2012-01-12 US disclosed
US-7973069-B2 Methods for treating hepatitis C PTC THERAPEUTICS, INC. (US) 2011-07-05 US disclosed
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-12-02 US disclosed
US-20100292187-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C OAT, HAVCR2, HCCS NPC1 297/4885KMT2A 3974/4885MEN1 4815/4885
US-20100292187-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, EIF2AK2, MAVS NPC1 87/4885KMT2A 4464/4885MEN1 4800/4885
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, EIF2AK2, MAVS NPC1 87/4885KMT2A 4464/4885MEN1 4800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.